Evaluation of high resolution gel β2-transferrin for detection of cerebrospinal fluid leak

被引:35
作者
McCudden, Christopher R. [1 ]
Senior, Brent A. [2 ]
Hainsworth, Shirley [3 ]
Oliveira, Walter [4 ]
Silverman, Lawrence M. [4 ]
Bruns, David E. [4 ]
Hammett-Stabler, Catherine A. [3 ]
机构
[1] Univ Ottawa, Ottawa Hosp, Dept Pathol & Lab Med, Div Biochem, Ottawa, ON K1H 8L6, Canada
[2] Univ N Carolina, Dept Surg, Div Neurosurg,Sch Med, Div Rhinol Allergy Sinus Surg,Dept Otolaryngol, Chapel Hill, NC USA
[3] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA
[4] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA
关键词
beta(2)-transferrin; CSF fistula; immunofixation; sensitivity; specificity; BETA-TRACE PROTEIN; SENSITIVE MARKER; ELECTROPHORESIS; NASAL; IDENTIFICATION; TRANSFERRIN; RHINORRHEA; ASSAY; EAR;
D O I
10.1515/cclm-2012-0408
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Cerebrospinal fluid (CSF) leaks are potentially life-threatening conditions that can be diagnosed by detection of beta(2)-transferrin using protein electrophoresis. Another less commonly available test is beta-trace protein quantitation using immunoassay. The objectives of this study were to evaluate a new immunofixation-based beta(2)-transferrin test for detection of CSF leaks and to compare it to an existing agarose gel electrophoresis test and beta-trace protein immunoassay. Methods: For method comparison, 63 consecutive samples from physician-ordered beta(2)-transferrin tests were analyzed using two different electrophoresis methods, agarose gel fractionation followed by acid-violet staining, and high resolution agarose gel electrophoresis followed by beta(2)-transferrin immunofixation. A subset of samples (16/63) were analyzed for beta-trace protein. Results were compared against patient chart data for the presence of a CSF leak. Additional studies were performed to assess the stability, detection limit, and analytical specificity of the beta(2)-transferrin immunofixation test. Results: The beta(2)-transferrin immunofixation test had a sensitivity of 100 % (40/40) and specificity of 71 % (12/17) for detection of CSF leaks. By comparison, the agarose gel test had a sensitivity of 87 % (35/40) and specificity of 94 % (16/17). beta-trace protein had a sensitivity of 100 % (10/10) and specificity of 86 % (5/6). Serum and saliva could be differentiated from CSF by the beta(2)-transferrin immunofixation test based on their migration patterns. However, whole blood samples appeared positive for beta(2)-transferrin at a threshold of similar to 4 g/L hemoglobin. At a cut-off of 3 mg/L, beta-trace protein was increased in 10/10 cases with documented CSF leak and in 1/6 patients without CSF leak. Conclusions: Both the new immunofixation test for beta(2)-transferrin and the beta-trace protein were effective at detecting CSF leaks. Users of the beta(2)-transferrin immunofixation test should be cautioned against interpreting samples with blood contamination.
引用
收藏
页码:311 / 315
页数:5
相关论文
共 22 条
[1]  
[Anonymous], 2011, R LANG ENV STAT COMP
[2]   Predictive values of β-trace protein (prostaglandin D synthase) by use of laser-nephelometry assay for the identification of cerebrospinal fluid [J].
Bachmann, G ;
Petereit, H ;
Djenabi, U ;
Michel, O .
NEUROSURGERY, 2002, 50 (03) :571-576
[3]   Beta-trace protein as sensitive marker for liquorrhea [J].
Bachmann, G ;
Petereit, H .
ACTA NEUROLOGICA SCANDINAVICA, 2004, 110 (05) :337-338
[4]   Clinical experience with beta-trace protein as a marker for cerebrospinal fluid [J].
Bachmann, G ;
Nekic, M ;
Michel, O .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2000, 109 (12) :1099-1102
[5]  
Buchman CA, 1999, AM J OTOL, V20, P174
[6]  
Burkhard PR, 2001, ELECTROPHORESIS, V22, P1826, DOI 10.1002/1522-2683(200105)22:9<1826::AID-ELPS1826>3.0.CO
[7]  
2-L
[8]  
Canty A.R., BOOT BOOTSTRAP R S P
[9]   Separation of β2-transferrin by denaturing gel electrophoresis to detect cerebrospinal fluid in ear and nasal fluids [J].
Görögh, T ;
Rudolph, P ;
Meyer, JE ;
Werner, JA ;
Lippert, BM ;
Maune, S .
CLINICAL CHEMISTRY, 2005, 51 (09) :1704-1710
[10]  
Grantham VV, 2006, J NUCL MED TECHNOL, V34, P48